Evidence map›Paper›PMID 38863067›Full record

ArticleTropical medicine and health2024

Impact of targeted drug administration and intermittent preventive treatment for forest goers using artesunate-pyronaridine to control malaria outbreaks in Cambodia.

Dysoley Lek, Nguon Sokomar, Top Samphornarann, Jeanne Rideout, Saad El-Din Hassan, Tol Bunkea, Saing Sam Ath, Rothpisey Seng, John Hustedt, Thomas J Peto and 4 more

Abstract read
In one paragraph

Article in Tropical medicine and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dysoley LekNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia. soleycnm@gmail.com.
Nguon SokomarCambodia Malaria Elimination Project2, University Research Company Ltd., Phnom Penh, Cambodia.
Top SamphornarannCambodia Malaria Elimination Project2, University Research Company Ltd., Phnom Penh, Cambodia.
Jeanne RideoutCambodia Malaria Elimination Project2, University Research Company Ltd., Phnom Penh, Cambodia.
Saad El-Din HassanCambodia Malaria Elimination Project2, University Research Company Ltd., Phnom Penh, Cambodia.
Tol BunkeaNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
Saing Sam AthNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
Rothpisey SengNational Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.
John HustedtCambodia Malaria Elimination Project2, University Research Company Ltd., Phnom Penh, Cambodia.
Thomas J PetoMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jayme HughesClinton Health Access Initiative, Phnom Penh, Cambodia.
Ke KimmenProvincial Health Department, Pursat, Cambodia.
Khoy DyClinton Health Access Initiative, Phnom Penh, Cambodia.
Bipin AdhikariMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Bipin@tropmedres.ac.ORCID http://orcid.org/0000-0001-8981-3910

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe national malaria programme of Cambodia targets the rapid elimination of all human malaria by 2025. As clinical cases decline to near-elimination levels, a key strategy is the rapid identification of malaria outbreaks triggering effective action to interrupt local transmission. We report a comprehensive, multipronged management approach in response to a  2022 Plasmodium falciparum outbreak in Kravanh district, western Cambodia.

methodsThe provincial health department of Pursat in conjunction with the Center for Parasitology, Entomology and Malaria Control (CNM) identified villages where transmission was occurring using clinical records, and initiated various interventions, including the distribution of insecticide-treated bed nets, running awareness campaigns, and implementing fever screening with targeted drug administration. Health stations were set up at forest entry points, and later, targeted drug administrations with artesunate-pyronaridine (Pyramax) and intermittent preventive treatment for forest goers (IPTf) were implemented in specific village foci. Data related to adherence and adverse events from IPTf and TDA were collected. The coverage rates of interventions were calculated, and local malaria infections were monitored.

resultsA total of 942 individuals were screened through active fever surveillance in villages where IPTf and TDA were conducted. The study demonstrated high coverage and adherence rates in the targeted villages, with 92% (553/600) coverage in round one and 65% (387/600) in round two. Adherence rate was 99% (551/553) in round one and 98% (377/387) in round two. The study found that forest goers preferred taking Pyramax over repeated testing consistent with the coverage rates: 92% in round one compared to 65% in round two. All individuals reachable through health stations or mobile teams reported complete IPTf uptake. No severe adverse events were reported. Only six individuals reported mild adverse events, such as loss of energy, fever, abdominal pain, diarrhoea, and muscle aches. Two individuals attributed their symptoms to heavy alcohol intake following prophylaxis.

conclusionsThe targeted malaria outbreak response demonstrated high acceptability, safety, and feasibility of the selected interventions. Malaria transmission was rapidly controlled using the available community resources. This experience suggests the effectiveness of the programmatic response for future outbreaks.

Indexed as

Artesunate–pyronaridineCambodiaIntermittent preventive treatmentOutbreak response, forest goersTargeted drug administration

Identifiers

PMID38863067
PMCPMC11165738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.